Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Biomarkers. Author manuscript; available in PMC 2010 May 1.
Published in final edited form as:
PMCID: PMC2819481

Plasma Levels of S100A4 in Portopulmonary Hypertension


We previously showed that a single nucleotide polymorphism in S100A4 was associated with developing portopulmonary hypertension (PPHTN) in patients with advanced liver disease. We aimed to determine the association between plasma levels of S100A4 and PPHTN.

We performed a case-control study of patients with advanced liver disease. Cases with PPHTN had mean pulmonary artery pressure > 25 mm Hg, pulmonary vascular resistance > 240 dynes-sec · cm−5, and pulmonary capillary wedge pressure ≤15 mm Hg. Controls with liver disease had right ventricular systolic pressure < 40 mm Hg and normal right atrial and ventricular morphology by echocardiography. Plasma samples were assayed for S100A4.

The study sample included 14 cases with PPHTN and 32 liver disease controls. The mean age for both cases and controls was 52 ± 9 yrs. Eighty percent of cases were female compared to 42% of controls (p = 0.02). There was no difference in S100A4 levels between cases and controls (p = 0.53). Both groups had significantly higher S100A4 levels than healthy volunteers (p < 0.05).

There was no significant difference in plasma levels of S100A4 between PPHTN patients and controls with liver disease, although liver disease itself was associated with increased S100A4 levels.

Keywords: portal hypertension, pulmonary arterial hypertension, genetic susceptibility, S100A4


Experimental models of pulmonary arterial hypertension (PAH) have implicated numerous genes in its pathogenesis. One such gene is S100A4, an intracellular calcium binding protein which causes pulmonary vascular remodeling in transgenic mice over-expressing the gene product (1). S100A4 also plays a role in tissue remodeling in lung and liver fibrogenesis (2,3) and metastatic tumor invasion (4).

PAH associated with portal hypertension, also known as portopulmonary hypertension (PPHTN), shares many pathological features with idiopathic and familial PAH (5). Approximately 5% of patients with cirrhosis being evaluated for liver transplantation have PPHTN (68), which may increase morbidity and mortality and greatly complicate liver transplantation (9,10).

There have been few studies of circulating biomarkers which characterize patients with PPHTN. We have previously shown that genetic variability in a S100A4 single nucleotide polymorphism (SNP) is associated with the risk of PPHTN in patients with liver disease (11). In the current study, we aimed to determine whether plasma levels of S100A4 were higher in patients with PPHTN compared to patients with advanced liver disease without evidence of PPHTN and disease-free controls.


Study Design and Study Sample

The Pulmonary Vascular Complications of Liver Disease (PVCLD) study enrolled a cohort of 536 patients evaluated for liver transplantation or pulmonary hypertension at seven centers in the United States between 2003 and 2006. The only inclusion criterion was the presence of clinical portal hypertension with or without intrinsic liver disease. We excluded patients with evidence of active infection or recent (< two weeks) gastrointestinal bleeding, or who had undergone liver or lung transplantation. Full details of the cohort are published elsewhere (12).

We performed a case-control study within the PVCLD cohort. The study sample included newly-referred patients who were evaluated with transthoracic echocardiography (routinely performed for pre-transplant evaluation) during the study period. “Prevalent” patients who met the case definition (see below) were also included. We excluded patients with significant obstructive or restrictive lung disease, as previously defined (12). The study sample also excluded patients with human immunodeficiency virus infection (which may independently cause PAH), hepatocellular carcinoma or hepatic mass (which may affect S100A4 levels), or the presence of more than moderate aortic or mitral stenosis or regurgitation or significant left ventricular dysfunction by transthoracic echocardiography (which may result in pulmonary hypertension).

Case and Control Definitions

Cases with PPHTN met the following criteria at entry into the cohort: 1) mean pulmonary artery pressure > 25 mm Hg, pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) ≤ 15 mm Hg, and pulmonary vascular resistance > 240 dynes-s•cm−5 measured by right heart catheterization, and 2) no other etiology for pulmonary hypertension. Controls met the following echocardiographic criteria at entry into the cohort: 1) right ventricular (RV) systolic pressure < 40 mm Hg (if estimable) and 2) absence of right atrial or ventricular dilation, hypertrophy, or dysfunction. “Prevalent” cases who had previously undergone evaluation and were subsequently being treated (n = 2) were also included; data from the initial evaluation (before treatment) were used for these cases. It was recommended that patients with RV systolic pressure > 50 mm Hg with abnormal RV morphology by echocardiography undergo right heart catheterization.


Plasma was isolated from centrifuged whole blood and stored at −80°C. Plasma was then thawed and S100A4 concentration was assayed by enzyme linked immunosorbent assay (ELISA) (CircuLex, Nagano, Japan). All samples were assayed in duplicate according to manufacturer’s instructions (13). Plates were read on a microplate reader and analyzed with SoftMax (Molecular Devices, Toronto, Canada) for quantification. Five samples had repeat analysis for estimation of the intraclass correlation coefficient (ICC) with 95% confidence interval (95% CI). Details of S100A4 genotyping are provided elsewhere (11).

Data Analysis and Sample Size Calculation

We used Student’s t-tests, Wilcoxon rank sum tests, chi-square tests, Fisher’s exact tests, and Spearman’s rho, as appropriate. Fourteen cases with 32 controls provided 80% power to detect a difference in plasma S100A4 levels of 0.9 standard deviations with a logistic non-parametric adjustment (α = 0.05) (14).


Fourteen cases with PPHTN and 32 controls with liver disease were assayed for plasma S100A4 level and genotyped. The baseline demographics of the patients are shown in Table 1. The mean ± SD age for both cases and controls was 52 ± 9 yrs. Eighty percent of cases were female compared to 42% of controls (p = 0.03). There was no significant difference in the proportions of non-Hispanic whites between the two groups (p = 0.16). One patient with PPHTN was receiving bosentan and one patient was receiving intravenous epoprostenol; all other PPHTN cases were untreated at the time of assessment.

Table 1
Demographics and liver disease variables

The median plasma S100A4 level was 83 ng/ml (IQR 25-271 ng/ml) for cases compared to 84 ng/ml (IQR 12-156 ng/ml) for controls (p = 0.58) (Figure 1A). Both groups had significantly higher S100A4 levels than healthy volunteers without liver disease (p < 0.05). These findings did not change significantly after adjustment for gender (Data not shown). Inter-assay reliability for plasma S100A4 was excellent (ICC = 0.99, 95%CI 0.98–1.0).

Figure 1Figure 1
S100A4 level according to disease status (A) and genotype (B). Genotypes include one patient homozygous for the minor allele (CC), patients heterozygous for the minor allele (CG), and patients without the minor allele (GG). Black bar represents median ...

We then assessed the relationship of plasma S100A4 levels with genotype of the SNP rs743687 within the S100A4 locus. The median plasma S100A4 levels were 544 ng/ml in the one patient homozygous for the minor allele (CC), 147 ng/ml (IQR 19–405 ng/ml) in the eight heterozygous patients (CG), and 74 ng/ml (IQR 18–123 ng/ml) in the 53 patients without the minor allele (GG), consistent with a possible relationship between genotype and plasma S100A4 level (p = 0.11). (Figure 1B)


This is the first study to examine plasma S100A4 levels in patients with PPHTN and liver disease. While there was no significant difference in S100A4 levels between cases with PPHTN and liver disease controls, both groups had significantly higher levels than healthy controls without liver disease. We examined plasma level according to SNP genotype from S100A4 which suggested that the copy number of the minor allele might correlate with the plasma S100A4 levels.

The mechanism between S100A4 and PAH in animal models and humans is not clear. Merklinger et al showed that transgenic mice overexpressing S100A4 displayed increased thickness of the internal and external lamina of the pulmonary arteries (15). The elevation in RV systolic pressure seen in response to hypoxia failed to reverse with nitric oxide in the transgenic mice. The lungs of these mice showed upregulation of fibulin-5 and elastin expression, which are essential components of the extracellular matrix that contribute to vascular remodeling (16).

SNPs within the S100A4 locus have not been assessed in regards to their effect on the activity or expression of the gene product. We showed that the level of S100A4 might correlate with the SNP genotype associated with PPHTN, although concurrent processes such as hemolysis or inflammatory changes could also raise the plasma S100A4 levels S100A4 (17,18).

We assessed the value of plasma S100A4 as a biomarker of disease and found no significant differences between liver disease patients with or without PPHTN. However, the presence of liver disease itself likely led to increased plasma S100A4, which has been shown to be a robust marker of hepatic fibrosis (2). Indeed, it is possible that the elevated plasma S100A4 levels which characterize patients with advanced liver disease could serve as the milieu which permits other clinical, environmental, neurohormonal or genetic modifiers to trigger the occurrence of PAH in this setting.

There are limitations to our study. Despite having assembled a multicenter cohort of PPHTN patients, it remains a relatively rare disease leading to a small sample size. However, this study was adequately powered to detect a less than one standard deviation difference between the groups. It is possible that cases may have been misclassified as controls based on echocardiography without confirmatory right heart catheterization. To minimize this possibility, we set very stringent echocardiographic criteria for controls which essentially rule out PPHTN in patients with endstage liver disease.(19). We only examined the correlation of one SNP within the S100A4 locus with plasma levels. It may be important to define haplotypes which could have more substantial associations with the molecular phenotype.

In summary, there were no differences in plasma S100A4 levels between PPHTN patients and controls, which were greater than those of healthy controls. Our study showed that there might be a correlation between genotype variation and plasma S100A4 level. The presence of liver disease may nonspecifically increase plasma S100A4 or the high circulating levels of S100A4 in patients with advanced liver disease could facilitate the development of PPHTN.


We thank Charles A. Powell, M.D., May Huang, John O’Connor, Ph.D. and the other staff at the Irving Institute for Clinical and Translational Research for their assistance.

Funded by NIH grants DK064103, DK065958, RR00645, RR00585, RR00046, RR00032, RR024156 and HL67771.


The Pulmonary Vascular Complications of Liver Disease Study Group also includes: Columbia University: Jeffrey Okun, Daniel Rabinowitz, Evelyn M. Horn, Lori Rosenthal, Sonja Olsen, Jenna Reinen; Mayo Clinic: Vijay Shah, Russell Wiesner, Linda Stadheim; University of Alabama: J. Stevenson Bynon, Devin Eckhoff, Harpreet Singh, Rajasekhar Tanikella, Keith Wille, Dorothy Faulk; University of Colorado: Lisa Forman, David Badesch, Ted Perry; The University of North Carolina at Chapel Hill: Roshan Shrestha, Carrie Nielsen, Steven Zacks; University of Pennsylvania: Vivek Ahya, Harold Palevsky, Rajender Reddy, Michael Harhay, Sandra Kaplan; University of Southern California: Neil Kaplowitz, James Knowles.


Conflict of Interest: SMK has received lecture fees, consultancy fees, and/or other support from Actelion, Pfizer, Gilead, Lilly, Novartis, INO Therapeutics, United Therapeutics, Gerson Lehrman, and Clinical Advisors. MJK has provided consultation regarding possible clinical trials concerning portopulmonary hypertension for Gilead, United Therapeutics, and Actelion. Other authors have not declared a potential conflict of interest.


1. Greenway S, van Suylen RJ, Du Marchie Sarvaas G, Kwan E, Ambartsumian N, Lukanidin E, Rabinovitch M. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol. 2004 Jan;164(1):253–62. [PubMed]
2. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, Jones DE, Burt AD, Kirby JA. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest. 2008 Feb;88(2):112–23. [PubMed]
3. Lawson WE, Polosukhin VV, Zoia O, Stathopoulos GT, Han W, Plieth D, Loyd JE, Neilson EG, Blackwell TS. Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med. 2005 Apr 15;171(8):899–907. [PubMed]
4. Garrett SC, Varney KM, Weber DJ, Bresnick AR. S100A4, a mediator of metastasis. J Biol Chem. 2006 Jan 13;281(2):677–80. [PubMed]
5. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S–12S. [PubMed]
6. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, Bernuau J, Marty J, Lebrec D, Valla D, Durand F. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401–409. [PubMed]
7. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky HI. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl. 2005;11:1107–1111. [PubMed]
8. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology. 2006;44:1502–1510. [PubMed]
9. Sussman N, Kaza V, Barshes N, Stribling R, Goss J, O’Mahony C, Zhang E, Vierling J, Frost A. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant. 2006;6:2177–2182. [PubMed]
10. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, Pardo M, Jr, Marotta P, Uemoto S, Stoffel MP, Benson JT. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004;10:174–182. [PubMed]
11. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H, Knowles JA, Rabinowitz D, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Kawut SM. for the PVCLD Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Resp Crit Care Med. (In Press) [PMC free article] [PubMed]
12. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Brown RS, Jr, Fallon MB. for the Pulmonvary Vascular Complications of Liver Disease Study Group. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48(1):196–203. [PMC free article] [PubMed]
14. Hintze J. NCSS and PASS 2005. Number Cruncher Statistical Systems Kaysville; Utah: 2004.
15. Merklinger SL, Wagner RA, Spiekerkoetter E, Hinek A, Knutsen RH, Kabir MG, Desai K, Hacker S, Wang L, Cann GM, Ambartsumian NS, Lukanidin E, Bernstein D, Husain M, Mecham RP, Starcher B, Yanagisawa H, Rabinovitch M. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circ Res. 2005 Sep 16;97(6):596–604. [PubMed]
16. Yanagisawa H, Davis EC, Starcher BC, Ouchi T, Yanagisawa M, Richardson JA, Olson EN. Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. Nature. 2002 Jan 10;415(6868):168–71. [PubMed]
17. Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad Ø, Paus E. Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumour Biol. 2004 Jan–Apr;25(1–2):31–40. [PubMed]
18. Klingelhöfer J, Senolt L, Baslund B, Nielsen GH, Skibshøj I, Pavelka K, Neidhart M, Gay S, Ambartsumian N, Hansen BS, Petersen J, Lukanidin E, Grigorian M. Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2007 Mar;56(3):779–89. [PubMed]
19. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, Bernuau J, Marty J, Lebrec D, Valla D, Durand F. Hepatology. 2003 Feb;37(2):401–9. [PubMed]